Five-Year watch: tracking safety of blood cancer drug
NCT ID NCT07162181
Summary
This study aims to monitor the long-term safety of the drug pirtobrutinib in people with previously treated blood cancers like chronic lymphocytic leukemia and lymphoma. It is only open to a small group of 13 people who are already benefiting from the drug in a previous trial. Participants will receive treatment every 12 weeks and be followed for about five years to check for serious side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer hospital
NOT_YET_RECRUITINGBeijing, 100142, China
Contact Phone: •••-•••-••••
Contact
-
Blood Institute of the Chinese Academy of Medical science
NOT_YET_RECRUITINGTianjin, 300020, China
Contact Phone: •••-•••-••••
Contact
-
Harbin Medical University Cancer Hospital
NOT_YET_RECRUITINGHarbin, 150081, China
Contact Phone: •••-•••-••••
Contact
-
Shanghai East Hospital
ACTIVE_NOT_RECRUITINGShanghai, 200123, China
-
Sun Yat-sen University Cancer Center
NOT_YET_RECRUITINGGuangzhou, 510060, China
Contact Phone: •••-•••-••••
Contact
-
Union Hospital Tongji Medical College Huazhong University of Science and Technology
RECRUITINGWuhan, 430022, China
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.